AcelRx Pharma (ACRX) Reports In-Line Q3 EPS

Go back to AcelRx Pharma (ACRX) Reports In-Line Q3 EPS

AcelRx Pharma (ACRX) Announces 17.5M Share and Warrant Offering at $0.80/sh

November 15, 2021 6:46 AM EST

AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced it has entered into an agreement with two life sciences-focused investment funds that are existing and new stockholders in AcelRx, for the sale of 17,500,000 shares of common stock and warrants exercisable for an... More

AcelRx Pharma (ACRX) Acquires Lowell Therapeutics for $32.5M; Reports Q3 Results

November 15, 2021 6:00 AM EST

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the execution of a definitive merger agreement to acquire Lowell Therapeutics, Inc. (Lowell), a privately held company, and reported its third quarter 2021 financial results.

Lowell, Niyad and LTX-608 Overview

Lowell is a privately held company developing Niyad, a regional anticoagulant for the dialysis circuit during continuous renal replacement therapy for acute kidney injury patients in the hospital. Niyad is being studied under an investigational device... More